in

Coronavirus: United Kingdom advises against Pfizer / BioNTech vaccine in case of severe allergies

The United Kingdom was the first country to authorize the vaccine and began a massive vaccination campaign on Tuesday, aimed so far at caregivers and the elderly.

LBritish health authorities on Wednesday advised against inoculating Pfizer and BioNTech’s vaccine against the new coronavirus to people who have had “significant allergic reactions” in the past, two people having reacted badly to the first injections.

The United Kingdom was the first country to authorize the vaccine and began a massive vaccination campaign on Tuesday, aimed so far at caregivers and the elderly.

“Two people who had serious allergic reactions reacted badly,” said Stephen Powis, medical director of the National Health Service (NHS) for England. “Both are recovering well”.

These two people are prone to allergies to the point of always carrying adrenaline with them.

Recommendation

Therefore, the UK medicines agency, MHRA, has issued a recommendation not to vaccinate “anyone with a history of a significant allergic reaction to vaccines, drugs or food (such as anaphylactic reactions or those to who was advised to wear an epinephrine injector) ”.

Some 800,000 doses of this vaccine out of the 40 million ordered by the government will be administered initially.

Despite the speed to put it on the market, “we have not cut back” on safety, had assured Tuesday the boss of Pfizer, Albert Bourla, during a virtual round table in Geneva.

The United Kingdom is the European country most bereaved by the pandemic with more than 62,000 dead.

The success of the vaccination promises to be crucial for the government of Boris Johnson, much criticized for its management of the pandemic and facing the anger of some elected officials at the restrictions imposed in much of the country, with an enormous economic and social cost .

New York : Advocates demand a New York with accessible, safe, and people-first streets

Citigroup goes to trial to undo nearly $ 900 million mistake with Revlon